Next Article in Journal
Dose–Response Study of Microcystin Congeners MCLA, MCLR, MCLY, MCRR, and MCYR Administered Orally to Mice
Next Article in Special Issue
Animal Venom for Medical Usage in Pharmacopuncture in Korean Medicine: Current Status and Clinical Implication
Previous Article in Journal
Metabolism of Zearalenone in the Rumen of Dairy Cows with and without Application of a Zearalenone-Degrading Enzyme
Previous Article in Special Issue
Venom of the Red-Bellied Black Snake Pseudechis porphyriacus Shows Immunosuppressive Potential
 
 
Article

In Vitro and In Vivo Antibacterial Activity of Gliotoxin Alone and in Combination with Antibiotics against Staphylococcus aureus

1
Fundacion Instituto de Investigacion Sanitaria Aragon (IIS Aragon), Biomedical Research Centre of Aragon (CIBA), 50009 Zaragoza, Spain
2
Instituto de Carboquımica ICB-CSIC, 50018 Zaragoza, Spain
3
Department of Microbiology, Hospital Universitario Miguel Servet, IIS Aragón, 50009 Zaragoza, Spain
4
Department of Microbiology, University Clinic Hospital Lozano Blesa, 50009 Zaragoza, Spain
5
Department of Microbiology, Pediatrics, Radiology and Public Health, University of Zaragoza, 50009 Zaragoza, Spain
6
Aragon I+D Foundation (ARAID), 50018 Zaragoza, Spain
*
Authors to whom correspondence should be addressed.
Toxins 2021, 13(2), 85; https://doi.org/10.3390/toxins13020085
Received: 20 December 2020 / Revised: 19 January 2021 / Accepted: 21 January 2021 / Published: 23 January 2021
(This article belongs to the Special Issue Drug Development Using Natural Toxins)
Multidrug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) is one of the major causes of hospital-acquired and community infections and pose a challenge to the human health care system. Therefore, it is important to find new drugs that show activity against these bacteria, both in monotherapy and in combination with other antimicrobial drugs. Gliotoxin (GT) is a mycotoxin produced by Aspergillus fumigatus and other fungi of the Aspergillus genus. Some evidence suggests that GT shows antimicrobial activity against S. aureus in vitro, albeit its efficacy against multidrug-resistant strains such as MRSA or vancomycin-intermediate S. aureus (VISA) strainsis not known. This work aimed to evaluate the antibiotic efficacy of GT as monotherapy or in combination with other therapeutics against MRSA in vitro and in vivo using a Caenorhabditis elegans infection model. View Full-Text
Keywords: gliotoxin; Staphylococcus aureus; MRSA; VISA; vancomycin; synergism; resistance; antibiotic gliotoxin; Staphylococcus aureus; MRSA; VISA; vancomycin; synergism; resistance; antibiotic
Show Figures

Figure 1

MDPI and ACS Style

Esteban, P.; Redrado, S.; Comas, L.; Domingo, M.P.; Millán-Lou, M.I.; Seral, C.; Algarate, S.; Lopez, C.; Rezusta, A.; Pardo, J.; Arias, M.; Galvez, E.M. In Vitro and In Vivo Antibacterial Activity of Gliotoxin Alone and in Combination with Antibiotics against Staphylococcus aureus. Toxins 2021, 13, 85. https://doi.org/10.3390/toxins13020085

AMA Style

Esteban P, Redrado S, Comas L, Domingo MP, Millán-Lou MI, Seral C, Algarate S, Lopez C, Rezusta A, Pardo J, Arias M, Galvez EM. In Vitro and In Vivo Antibacterial Activity of Gliotoxin Alone and in Combination with Antibiotics against Staphylococcus aureus. Toxins. 2021; 13(2):85. https://doi.org/10.3390/toxins13020085

Chicago/Turabian Style

Esteban, Patricia, Sergio Redrado, Laura Comas, M. Pilar Domingo, M. Isabel Millán-Lou, Cristina Seral, Sonia Algarate, Concepción Lopez, Antonio Rezusta, Julian Pardo, Maykel Arias, and Eva M. Galvez. 2021. "In Vitro and In Vivo Antibacterial Activity of Gliotoxin Alone and in Combination with Antibiotics against Staphylococcus aureus" Toxins 13, no. 2: 85. https://doi.org/10.3390/toxins13020085

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop